Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Net Cash Flow: 2018-2024

Historic Net Cash Flow for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to $37.3 million.

  • Avidity Biosciences' Net Cash Flow rose 151.70% to $106.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.2 million, marking a year-over-year decrease of 107.02%. This contributed to the annual value of $37.3 million for FY2024, which is 124.01% up from last year.
  • Avidity Biosciences' Net Cash Flow amounted to $37.3 million in FY2024, which was up 124.01% from -$155.3 million recorded in FY2023.
  • Over the past 5 years, Avidity Biosciences' Net Cash Flow peaked at $227.1 million during FY2020, and registered a low of -$155.3 million during FY2023.
  • Moreover, its 3-year median value for Net Cash Flow was $19.9 million (2022), whereas its average is -$32.7 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first surged by 2,067.26% in 2022, then crashed by 878.37% in 2023.
  • Avidity Biosciences' Net Cash Flow (Yearly) stood at $227.1 million in 2020, then tumbled by 100.45% to -$1.0 million in 2021, then soared by 2,067.26% to $19.9 million in 2022, then crashed by 878.37% to -$155.3 million in 2023, then soared by 124.01% to $37.3 million in 2024.